



Results of MolMed's ARENEGYR (NGR-hTNF α) Phase I trial NGR002 presented at the ASCO Annual Meeting

Milan, Italy - June 2nd, 2007 – MolMed S.p.A., a biotech company focused on novel anticancer therapies, announced that results of a Phase I clinical trial of MolMed's novel vascular targeting agent ARENEGYR (NGR-hTNF α) were presented today at the 43rd ASCO Annual Meeting in Chicago (IL, USA), in a poster discussion session within the Section devoted to Developmental Therapeutics and Molecular Therapeutics.

The study, **Safety and anticancer activity of low dose regimen of NGRhTNF, a new vascular targeting agent, in solid advanced malignancies - NGR002 phase I trial** (ASCO Abstract Number 3540), evaluated the low dose range (0.2 - 1.6 $\mu\text{g}/\text{m}^2$) of ARENEGYR in heavily pretreated patients with refractory solid tumors, and indicated that ARENEGYR is extremely safe and able to induce long-lasting stabilisation of disease (≥ 6 months) in 5/16 patients. Consistently, dynamic imaging with magnetic resonance carried out in patients during treatment showed that ARENEGYR induces an antivascular effect.

Claudio Bordignon, President and Chief Executive Officer of MolMed, commented: "The favourable safety profile of ARENEGYR, along with its preliminary anticancer activity, convinced us to give way to the currently ongoing Phase II trials of 0.8 $\mu\text{g}/\text{m}^2$ ARENEGYR as single agent in several solid tumour histotypes, including colorectal cancer". Phase II trials of the same dose of ARENEGYR in combination with standard chemotherapeutic agents are in preparation.

About ARENEGYR

ARENEGYR is a vascular targeting agent (VTA) exploiting a tumour homing peptide (NGR) selectively binding solid tumour neovasculature, linked to the powerful anticancer cytokine hTNF α . The resulting molecule has unique biological properties: at low dose, it induces tumour vascular permeability and normalisation; at high dose, ARENEGYR causes tumour necrosis by vascular disruption. ARENEGYR is undergoing clinical development in three different programmes: as single agent, in both low- and high-dose ranges, and at low doses in combination with chemotherapeutic agents.

About MolMed

MolMed S.p.A is a biotechnology company focused on R&D and production of novel anticancer therapies. In addition to ARENEGYR, MolMed has two more anticancer products undergoing clinical validation: TK, a cell therapy-based product enabling safe haploidentical haematopoietic stem cell transplantation (haplo-HSCT) for the cure of high-risk leukaemia, that will enter into Phase III in 2007, and M3TK, a therapeutic vaccine now in Phase I/II for advanced-stage melanoma. MolMed's clinical pipeline is supported by a broad portfolio of therapeutic candidates, generated by its R&D programmes and building up an integrated strategy addressing cancer. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy.

For further information, please contact:
Holger Neecke, Business Development Manager

Phone: +39 02 212.77.1
e-mail: info@molmed.com